Navigation Links
Digimarc Board Approves $310 Million All-Cash Offer from L-1 Identity Solutions for Digimarc's ID Systems Business
Date:6/30/2008

r combined presence and knowledge of international markets will enhance our customer reach through an expanded portfolio of innovative credentialing solutions, including national ID cards."

L-1 believes that the combination of L-1 and Digimarc's Secure ID business will bring significant synergies and benefits to the identity management industry. The company's customers will have a choice of secure credentialing production systems, including central issuance, over-the-counter, and hybrid approaches that utilizes both methods. The combined security feature portfolios of the companies will deliver best-in-class protection to produce the most secure credentials possible. The industry knowledge of the combined teams will foster development of superior next-generation security functionality for future applications. The increase in industry knowledge and cross-border relationships will help secure identities across the globe in emerging markets such as Russia and Asia-Pacific, as well as with Canadian and Mexican biometric credentialing programs. Leveraged synergies between the businesses will reduce the cost structures of both organizations to drive greater operational efficiency and shareholder value. These benefits also will be passed directly to the customer for improved customer service from the combined call center and field service teams, bolstered competency of the entire organization from acquired back office systems and processes, and valuable savings with more competitive pricing from economies of scale.

Under the terms of the amended merger agreement, the tender offer is expected to commence on July 2, 2008, but no later than July 7, 2008 and remain open for 20 business days. The spin-off of the digital watermarking business will occur prior to the expiration date of the tender offer.

About L-1 Identity Solutions

L-1 Identity Solutions, Inc. (NYSE:

SOURCE L-1 Identity Solutions
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology news :

1. Statement by the American Egg Board and Egg Nutrition Center on AJCN study on egg consumption
2. Missouri board grants Washington University Sustainability Center $3 million
3. Solidus Networks, Inc. Seats New Board of Directors
4. New test finds diisobutyl phthalate in some cardboard food packaging -- recycling is the issue
5. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
6. Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors
7. TAU scientists probe deep questions aboard EcoOceans environmental research ship
8. Court Approves Scheme of Arrangement
9. Pitt receives $2.5 million to simulate and analyze brain, immune system activity
10. Manchester clears first hurdle in €170 million biobank building boom
11. Scientists find 245 million-year-old burrows of land vertebrates in Antarctica
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... , A new study of the Max Planck ... positive effect of dietary restriction on healthy ageing. Previous evidence ... dietary restriction increases longevity, but with a potential negative side ... less frequently with a reduced litter size on a low ...
(Date:12/3/2009)... Inc. (OTC Bulletin Board: BKYI), a leader in ... announced that a majority of its shareholders at ... sale of the company,s Law Enforcement Division to ... 98.6% were cast in favor and 1.2% were ...
(Date:12/3/2009)... plant and animal species can be likened to emptying a ... potential medicines into the trash, or replacing every local cuisine ... their habitats may not just make the world boring. New ... risk for catching some nasty disease. , "Habitat destruction and ...
Breaking Biology News(10 mins):How nutrition affects healthy aging 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3Species down, disease up 2Species down, disease up 3Species down, disease up 4D Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering 28IPO 29 on the Tel Aviv Stock Exchange 28TASE 29 4857 1D Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering 28IPO 29 on the Tel Aviv Stock Exchange 28TASE 29 4857 2D Pharm Raises NIS 85 Million in Rights Offering and Initial Public Offering 28IPO 29 on the Tel Aviv Stock Exchange 28TASE 29 4857 3New Data Supports ConvaTec Negative Pressure Wound Therapy 4855 1New Data Supports ConvaTec Negative Pressure Wound Therapy 4855 2New Data Supports ConvaTec Negative Pressure Wound Therapy 4855 3For Short Kids No Lack of Self Esteem 54617 1For Short Kids No Lack of Self Esteem 54617 2For Short Kids No Lack of Self Esteem 54617 3
... Center have discovered two genetic markers that appear to ... chronic obstructive pulmonary disease (COPD). , The findings ... and suggest that those who carry the markers may ... smoking before the first symptoms of COPD occur. , ...
... Kingston, ON Improved technology, partnerships and collaboration ... to dramatically expand the use of eye-movement tests ... Alcohol Spectrum Disorder (FASD). , "Our initial study ... of children who had to travel to Queen,s ...
... Runners, listen up: If your body is telling you that ... slow, it may be right. , A new study, published ... shows that the efficiency of human running varies with speed and ... she can cover the greatest distance with the least effort. ...
Other Biology News:Genetic irregularities linked to higher risk of COPD among smokers 2Fetal alcohol syndrome testing expands 2Optimum running speed is stride toward understanding human body form 2
(Date:12/2/2009)... Reportlinker.com announces that a new market research ... Drug Discovery Technologies - A Global ... ,, http://www.reportlinker.com/p0164246/Drug-Discovery-Technologies---A-Global-Update-of-Market-Trends--Opportunities.html ,, Drug discovery ... of every pharmaceutical company,s business strategy. There ...
(Date:12/2/2009)... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion ... trial of Cotara® in patients with relapsed glioblastoma multiforme ... is a targeted monoclonal antibody linked to a radioisotope ... Cotara specifically targets cells at the center of ...
(Date:12/2/2009)... Pepscan Holding NV,the Netherlands based biotechnology company focusing on ... announced that it,has appointed Wim E.M. Mol, Ph.D. as ... Dr. Mol will be responsible for all of Pepscans ... the company. He brings to,Pepscan more than 20 years ...
(Date:12/2/2009)... Dec. 2 S*BIO Pte Ltd today announced data ... The American Society of Hematology 51st Annual Meeting and ... on the clinical results from the Phase 1 dose-escalation ... (PK/PD) profile in dose levels ranging from 100 to ...
Breaking Biology Technology:Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 2Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 3Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 4Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 5Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 6Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 7Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 8Reportlinker Adds Drug Discovery Technologies - A Global Update of Market Trends & Opportunities 9Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Dutch Biotech Company Pepscan Appoints New CEO 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... Aug. 7 /PRNewswire-FirstCall/ - GeneNews Limited (TSX: GEN), ... the early,detection of diseases and personalized health management, ... quarter and year to date,ended June 30, 2008., ... ColonSentry(TM), a blood,test to assess a patient,s current ...
... today that Robert N. Butler, M.D., has been ... is the founder, Chief Executive Officer, and President ... research, policy, and education organization formed to educate ... and advise society on how to maximize the ...
... Record quarterly and Fiscal Year service revenue grows approximately 33% ... and 30%, respectively ... of 1.56 for the ... quarter, BOSTON, Aug. 6 PAREXEL International,Corporation (Nasdaq: PRXL ) today announced its financial ...
Other Biology Technology:GeneNews Announces Second Quarter Results 2GeneNews Announces Second Quarter Results 3GeneNews Announces Second Quarter Results 4GeneNews Announces Second Quarter Results 5GeneNews Announces Second Quarter Results 6GeneNews Announces Second Quarter Results 7GeneNews Announces Second Quarter Results 8 Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 2 Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 3 Dr. Robert N. Butler Appointed to Board of Directors of BioTime, Inc. 4PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 2PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 3PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 4PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 5PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 6PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 7PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 8PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 9PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 10PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 11PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 12PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 13PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results 14
These Costar 96-well, flat-bottom polystyrene EIA plates are used for EIAs, ELISAs, and other protein binding assays. Supplied as box of 100 (20 packages; 5 plates per package)....
... GenomeLab GeXP Genetic Analysis System provides high-throughput, ... PCR*. The systems patented priming strategy ... PCR analysis to just a few genes ... more genes per reaction and more samples ...
... Shift Assay provides a convenient method to probe ... of MDR1 substrates. Thus, the kit may be ... molecules act as transport substrates for MDR1. Because ... of MDR1 substrates, the MDR1 Shift Assay can ...
... The Chemicon Detergent-OUT Kit is a simple ... protein solutions. Removes detergents without significant ... the protein solution on the Detergent-OUT Spin ... The Med column is suitable for ...
Biology Products: